Hemab Therapeutics Holdings, Inc. reporting persons led by RA Capital Management, L.P. report beneficial ownership of 7,729,773 shares of common stock, equal to 16.6% of the class. The filing states 46,705,410 shares outstanding as of May 4, 2026.
The filing discloses that the 7,729,773 figure reflects shared voting and shared dispositive power held by RA Capital and named individuals, and that 6,365,783 of those shares are held directly by RA Capital Healthcare Fund, L.P. The filing also explains delegation of voting and disposition authority to RA Capital and contains disclaimers of beneficial ownership by certain funds and the reporting persons.
Hemab Therapeutics Holdings, Inc. reported multiple open-market purchases of its Common Stock by entities associated with RA Capital. Over May 7–11, RA Capital–managed funds bought a total of 51,258 shares at weighted average prices generally between about $23.78 and $25.00 per share, across several transaction ranges noted in the footnotes. Following these purchases, RA Capital–related entities reported indirect ownership of 6,365,783 shares of Hemab common stock. Shares are held directly by RA Capital Healthcare Fund LP, RA Capital Nexus II Fund LP, and RA Capital Nexus IV Fund LP, while RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah act as investment managers and disclaim beneficial ownership except to the extent of their pecuniary interests.
Access Industries affiliates report a significant stake in Hemab Therapeutics Holdings, Inc. AI DEN-MAB LLC and related entities disclose beneficial ownership of 4,876,344 shares of common stock, representing 10.4% of Hemab’s outstanding shares following its initial public offering.
AI DEN-MAB built the position through preferred investments in Hemab ApS that later converted into 3,776,344 common shares after a 22-for-one stock split, plus a purchase of 1,100,000 shares in the IPO at $18.00 per share. The group describes the investment as made in the ordinary course of business but may buy or sell more shares over time.
AI DEN-MAB is subject to a 180-day lock-up from April 30, 2026, limiting sales or hedging of its Hemab holdings. It also holds registration rights under an Investors' Rights Agreement, including demand, shelf and piggyback rights once the IPO lock-up period and related conditions are met.
Hemab Therapeutics Holdings, Inc. reported that Laura Tadvalkar, Ph.D. has resigned from its board of directors, effective May 8, 2026. The company states that her resignation is not related to any disagreement with Hemab on operations, policies, or practices.
Hemab Therapeutics Holdings, Inc. passive ownership disclosure: Deep Track-related entities reported beneficial ownership positions in Hemab common stock totaling up to 3,600,996 shares (8.15%) as of May 8, 2026. The filing states the ownership percentages use 44,192,910 shares outstanding as of May 1, 2026.
The Schedule 13G is a joint filing by Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; Deep Track Special Opportunities Fund, LP; and David Kroin, identifying shared voting and dispositive power over reported holdings.
Hemab Therapeutics Holdings, Inc. reported that funds managed by RA Capital increased their indirect stake through a mix of open‑market purchases and preferred stock conversions. Over May 4–6, 2026, the funds bought 2,840,429 shares of common stock at prices including $18.00, $24.59, $25.00, $23.77 and $24.83 per share. In connection with the issuer’s initial public offering, all Series A, B and C preferred shares automatically converted to common stock on a 22‑for‑1 basis for no additional consideration. Following these transactions, indirect holdings reported in one line reached 6,314,525 shares of common stock.